Key Takeaways:
-
Iksuda’s PermaLink technology can design ADCs insusceptible to drug de-conjugation.
-
It has two lead assets targeting CD19 and HER2, respectively, in Phase I development.
-
The firm is in the midst of a minimum $70m series B raise to help reach proof-of-concept.
Iksuda Therapeutics is on mission to design and develop more securely conjugated and efficacious antibody-drug conjugates (ADCs) for the treatment of
The UK firm’s story goes back to 2007 when investor IP Group founded a company called Glythera with two platforms focused respectively on half-life extension and conjugation technology (PermaLink)
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?